Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent.
Claims data
Cohort study
Influenza
Post-COVID
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
06
04
2024
accepted:
04
10
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
epublish
Résumé
Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as influenza. We investigated a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last influenza outbreak in 2018 and followed them up to 18 months. We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the influenza or contemporary control cohort. The persistence of post-viral symptoms was similar between COVID-19 and influenza. Post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as influenza.
METHODS
METHODS
We investigated a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last influenza outbreak in 2018 and followed them up to 18 months.
RESULTS
RESULTS
We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the influenza or contemporary control cohort. The persistence of post-viral symptoms was similar between COVID-19 and influenza.
CONCLUSION
CONCLUSIONS
Post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.
Identifiants
pubmed: 39385128
doi: 10.1186/s12879-024-10059-y
pii: 10.1186/s12879-024-10059-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1126Informations de copyright
© 2024. The Author(s).
Références
Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911–23.
doi: 10.1038/s41591-022-01810-6
pubmed: 35585196
Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, et al. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459.
doi: 10.3389/fimmu.2023.1129459
pubmed: 36969241
pmcid: 10034329
Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, Ekka-Zohar A, Ben David SS, Lerner U, Bivas-Benita M, Greenfeld S. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.
doi: 10.1136/bmj-2022-072529
pubmed: 36631153
Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347–57.
doi: 10.1038/s41591-023-02521-2
pubmed: 37605079
pmcid: 10504070
Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, Scott JT, O’Donnell CA, Blane DN, Browne S, et al. Natural history of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14:3504.
doi: 10.1038/s41467-023-39193-y
pubmed: 37311808
pmcid: 10263377
Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, Wende D, Vivirito A, Toepfner N, Ehm F, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med. 2022;19:e1004122.
doi: 10.1371/journal.pmed.1004122
pubmed: 36355754
pmcid: 9648706
Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–15.
doi: 10.1001/jama.2022.18931
pmcid: 9552043
Chang H, Kuo CF, Yu TS, Ke LY, Hung CL, Tsai SY. Increased risk of chronic fatigue syndrome following infection: a 17-year population-based cohort study. J Transl Med. 2023;21:804.
doi: 10.1186/s12967-023-04636-z
pubmed: 37951920
pmcid: 10638797
Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129.
doi: 10.1016/S2213-2600(21)00031-X
pubmed: 33453162
pmcid: 7832375
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7.
Buda S, Preuß B,Biere B, Wedde M, Dürrwald R. Vorläufige Ergebnisse zur Wirksamkeit der saisonalen Influenzaimpfung bei ambulant behandelten Patienten in der Saison 2017/18 in Deutschland. Epid Bull. 2018;6:69–70.
Rondy M, Kissling E, Emborg H-D, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, McMenamin J, Valenciano M. group I-MI-M: Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Eurosurveillance. 2018;23:18–00086.
doi: 10.2807/1560-7917.ES.2018.23.9.18-00086
pubmed: 29510782
pmcid: 5840921
Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57–62.
doi: 10.1016/j.puhe.2022.02.013
pubmed: 35378455
Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Med. 2023;20:e1004194.
doi: 10.1371/journal.pmed.1004194
pubmed: 37068113
pmcid: 10150975
Munblit D, Nicholson T, Akrami A, Apfelbacher C, Chen J, De Groote W, Diaz JV, Gorst SL, Harman N, Kokorina A, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10:715–24.
doi: 10.1016/S2213-2600(22)00169-2
pubmed: 35714658
pmcid: 9197249
Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383–8.
doi: 10.1097/EDE.0b013e3181d61eeb
pubmed: 20335814
pmcid: 3053408
Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259–64.
doi: 10.1038/s41586-021-03553-9
pubmed: 33887749
Hilbe JM. Negative binomial regression. 2nd ed. Cambridge: Cambridge University Press; 2011.
doi: 10.1017/CBO9780511973420
Cameron AC, Trivedi PK. Regression Analysis of Count Data Book. 2nd ed. Cambridge: Cambridge University Press; 2013.
doi: 10.1017/CBO9781139013567
Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
R Core Development Team: R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
Reme BA, Gjesvik J, Magnusson K. Predictors of the post-COVID condition following mild SARS-CoV-2 infection. Nat Commun. 2023;14:5839.
doi: 10.1038/s41467-023-41541-x
pubmed: 37730740
pmcid: 10511472
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, et al. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS-CoV-2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort. Infection. 2023;51(6):1–16.
doi: 10.1007/s15010-023-02043-6
Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 1957;2022:13.
Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V, Fácila L, Ariza A, Núñez J, Cordero A. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020;21:915–8.
doi: 10.1016/j.jamda.2020.05.045
pubmed: 32674819
pmcid: 7247470
Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong ASF, Silverwood RJ, Di Gessa G, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.
doi: 10.1038/s41467-022-30836-0
pubmed: 35764621
pmcid: 9240035
Fernández-de-las-Peñas C, Torres-Macho J, Catahay JA, Macasaet R, Velasco JV, Macapagal S, Caldararo M, Henry BM, Lippi G, Franco-Moreno A, Notarte KI. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review. Infection. 2024;52(1):43–58.
Ao D, He X, Liu J, Xu L. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal Transduct Target Ther. 2023;8:466.
doi: 10.1038/s41392-023-01724-w
pubmed: 38129394
pmcid: 10739883
Pan JQ, Tian ZM, Xue LB. Hyperbaric Oxygen Treatment for Long COVID: From Molecular Mechanism to Clinical Practice. Curr Med Sci. 2023;43:1061–5.
doi: 10.1007/s11596-023-2799-1
pubmed: 37924387
Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A, Fehr JS, Puhan MA. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381:e074425.
doi: 10.1136/bmj-2022-074425
pubmed: 37257891
pmcid: 10230608
Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863–76.
doi: 10.1016/S2213-2600(22)00126-6
pubmed: 35568052
pmcid: 9094732
Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect Dis. 2024;24(3):239–55.
Quinn KL, Stukel TA, Huang A, Abdel-Qadir H, Altaf A, Bell CM, Cheung AM, Detsky AS, Goulding S, Herridge M, et al. Comparison of Medical and Mental Health Sequelae Following Hospitalization for COVID-19, Influenza, and Sepsis. JAMA Intern Med. 2023;183:806–17.
doi: 10.1001/jamainternmed.2023.2228
pubmed: 37338892
pmcid: 10282961
Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJW, Chan YH, Teo NWY, Charn TC, See A, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503.
doi: 10.1136/bmj-2021-069503
pubmed: 35896188
Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, Lindmark K, Fors Connolly AM. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590.
doi: 10.1136/bmj-2021-069590
pubmed: 35387772
Fairweather D, Beetler DJ, Di Florio DN, Musigk N, Heidecker B, Cooper LT Jr. COVID-19, Myocarditis and Pericarditis. Circ Res. 2023;132:1302–19.
doi: 10.1161/CIRCRESAHA.123.321878
pubmed: 37167363
pmcid: 10171304
Gornyk D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Heise J-K, Maaß H, Ortmann J, Kessel B, Kemmling Y, et al. SARS-CoV-2 Seroprevalence in Germany. Dtsch Arztebl International. 2021;118:824.